New funds to Embrace rare genetic disorder research
Posted: 3 September 2024 Scientists at La Trobe University have received nearly $140,000 from rare disease charity Archie’s Embrace to investigate an under-researched genetic disorder which causes early-onset neurodegeneration in babies. The disorder, which causes a deficiency of…
Non-invasive testing a way of the future
Posted: 3 September 2024 A new collaborative study between the RMH and WEHI is the latest technology to test for early markers of kidney rejection via a simple urine test, hoping to bypass the need for invasive biopsies. Researchers at the RMH and WEHI are…
New clue into the curious case of our ageing immune system
Posted: 3 September 2024 A WEHI study could help solve a long-standing mystery into why a key immune organ in our bodies shrinks and loses its function as we get older. The thymus is an organ essential for…
Two-in-one breakthrough: Cutting-edge immunotherapy could hold promise for incurable brain cancer
Posted: 3 September 2024 Researchers at WEHI have identified a promising new two-in-one treatment that not only targets and destroys an aggressive form of brain cancer, but also helps the immune system develop a lasting defence against it. This…
Scientists discover how the body’s killer cells attack cancer
Posted: 3 September 2024 An international team of scientists are on the verge of a cancer breakthrough after working out how the body’s immune system targets cells devastated by the disease. A new study published in the journal Science…
Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
Posted: 28 August 2024 Telix today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara®[1], 18F-floretyrosine or 18F-FET), an investigational PET[2] agent for the characterisation of progressive or…
Finger-prick test could screen for early Alzheimer’s
Posted: 28 August 2024 GPs could soon be able to screen their patients for Alzheimer’s Disease (AD) using a simple handheld device developed by Monash engineers. Monash engineers have developed the first-of-a-kind finger-prick blood test with ‘needle-in-a hay-stack’…
Life prolonging breast cancer drug receives expanded access on the PBS
Posted: 28 August 2024 Australians diagnosed with a type of metastatic breast cancer will now have access to a life prolonging treatment under the Pharmaceutical Benefits Scheme (PBS) from 1 September 2024. Trastuzumab deruxtecan (Enhertu®) will be expanded on…
$66 million in 10 years: groundbreaking strategic investment fund to drive biomedical innovation
Posted: 28 August 2024 With a grand vision of investing $66 million over 10 years in groundbreaking medical innovations, WEHI’s first strategic investment fund, 66ten, is the largest internal pre-seed and seed fund created by an Australian medical…
Delivery of New Colorectal Cancer Multiplex Assay Alpha Kit
Posted: 28 August 2024 Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) (Rhythm or the Company) advises it has received the first batch of the Alpha version of the multiplex antibody detection kits developed and…
Lumos Diagnostics seals deal to advance point-of-care test to monitor liver health
Posted: 27 August 2024 Lumos Diagnostics (ASX:LDX) has extended its existing deal with the Burnet Diagnostics Initiative to progress a new point-of-care test for use in monitoring liver health in an upcoming clinical trial. As part of the deal,…
Sleep tight: New wearable sensor sheds light on getting the best rest
Posted: 27 August 2024 In a world first, a new wearable device developed by Monash University researchers will help to record the impact of artificial light on our bodies for sound sleep, improved mental wellbeing and treating chronic…
